Yonsei Med J.  2011 Nov;52(6):892-897. 10.3349/ymj.2011.52.6.892.

Glutamine as an Immunonutrient

• Kim H

• KMID: 1058807
• DOI: http://doi.org/10.3349/ymj.2011.52.6.892

Abstract

Dietary supplementation with nutrients enhancing immune function is beneficial in patients with surgical and critical illness. Malnutrition and immune dysfunction are common features in hospitalized patients. Specific nutrients with immunological and pharmacological effects, when consumed in amounts above the daily requirement, are referred to as immune-enhancing nutrients or immunonutrients. Supplementation of immunonutrients is important especially for patients with immunodeficiency, virus or overwhelming infections accompanied by a state of malnutrition. Representative immunonutrients are arginine, omega-3 fatty acids, glutamine, nucleotides, beta-carotene, and/or branched-chain amino acids. Glutamine is the most abundant amino acid and performs multiple roles in human body. However, glutamine is depleted from muscle stores during severe metabolic stress including sepsis and major surgery. Therefore it is considered conditionally essential under these conditions. This review discusses the physiological role of glutamine, mode and dose for glutamine administration, as well as improvement of certain disease state after glutamine supplementation. Even though immunonutrition has not been widely assimilated by clinicians other than nutritionists, immunonutrients including glutamine may exert beneficial influence on diverse patient populations.

Keyword

Glutamine; immune dysfunction; malnutrition; critical illness INTRODUCTION

MeSH Terms

Animals
Critical Illness
Glutamine/blood/metabolism/*therapeutic use
Humans
Immunity/drug effects
Inflammation/drug therapy/metabolism
Malnutrition

Reference

1. Kudsk KA, Minard G, Croce MA, Brown RO, Lowrey TS, Pritchard FE, et al. A randomized trial of isonitrogenous enteral diets after severe trauma. An immune-enhancing diet reduces septic complications. Ann Surg. 1996. 224:531–540.

2. Koletzko S. Progress of enteral feeding practice over time: moving from energy supply to patient- and disease-adapted formulations. Nestle Nutr Workshop Ser Pediatr Program. 2010. 66:41–54.

3. Kudsk KA, Croce MA, Fabian TC, Minard G, Tolley EA, Poret HA, et al. Enteral versus parenteral feeding. Effects on septic morbidity after blunt and penetrating abdominal trauma. Ann Surg. 1992. 215:503–511.

4. Alivizatos V, Athanasopoulos P, Makris N, Karageorgos N. Early postoperative glutamine-supplemented parenteral nutrition versus enteral immunonutrition in cancer patients undergoing major gastrointestinal surgery. J BUON. 2005. 10:119–122.

5. Słotwiński R, Słotwińska S, Kędziora S, Bałan BJ. Innate immunity signaling pathways: links between immunonutrition and responses to sepsis. Arch Immunol Ther Exp (Warsz). 2011. 59:139–150.

6. Kurmis R, Parker A, Greenwood J. The use of immunonutrition in burn injury care: where are we? J Burn Care Res. 2010. 31:677–691.

7. Mizock BA. Immunonutrition and critical illness: an update. Nutrition. 2010. 26:701–707.

8. Kudsk KA. Immunonutrition in surgery and critical care. Annu Rev Nutr. 2006. 26:463–479.

9. Beisel WR. History of nutritional immunology: introduction and overview. J Nutr. 1992. 122:591–596.

10. Grimble RF. Immunonutrition. Curr Opin Gastroenterol. 2005. 21:216–222.

11. Souba WW. Glutamine: a key substrate for the splanchnic bed. Annu Rev Nutr. 1991. 11:285–308.

12. Wilmore DW, Smith RJ, O'Dwyer ST, Jacobs DO, Ziegler TR, Wang XD. The gut: a central organ after surgical stress. Surgery. 1988. 104:917–923.

13. Windmueller HG, Spaeth AE. Uptake and metabolism of plasma glutamine by the small intestine. J Biol Chem. 1974. 249:5070–5079.

14. Lacey JM, Wilmore DW. Is glutamine a conditionally essential amino acid? Nutr Rev. 1990. 48:297–309.

15. Brasse-Lagnel CG, Lavoinne AM, Husson AS. Amino acid regulation of mammalian gene expression in the intestine. Biochimie. 2010. 92:729–735.

16. Gstraunthaler G, Landauer F, Pfaller W. Ammoniagenesis in LLC-PK1 cultures: role of transamination. Am J Physiol. 1992. 263:C47–C54.

17. Wischmeyer PE. Glutamine: mode of action in critical illness. Crit Care Med. 2007. 35:S541–S544.

18. Rhoads JM, Argenzio RA, Chen W, Rippe RA, Westwick JK, Cox AD, et al. L-glutamine stimulates intestinal cell proliferation and activates mitogen-activated protein kinases. Am J Physiol. 1997. 272:G943–G953.

19. Huang Y, Shao XM, Neu J. Immunonutrients and neonates. Eur J Pediatr. 2003. 162:122–128.

20. Wessner B, Strasser EM, Spittler A, Roth E. Effect of single and combined supply of glutamine, glycine, N-acetylcysteine, and R,S-alpha-lipoic acid on glutathione content of myelomonocytic cells. Clin Nutr. 2003. 22:515–522.

21. Cetinbas F, Yelken B, Gulbas Z. Role of glutamine administration on cellular immunity after total parenteral nutrition enriched with glutamine in patients with systemic inflammatory response syndrome. J Crit Care. 2010. 25:661.e1–661.e6.

22. dos Santos RG, Viana ML, Generoso SV, Arantes RE, Davisson Correia MI, Cardoso VN. Glutamine supplementation decreases intestinal permeability and preserves gut mucosa integrity in an experimental mouse model. JPEN J Parenter Enteral Nutr. 2010. 34:408–413.

23. Andrews FJ, Griffiths RD. Glutamine: essential for immune nutrition in the critically ill. Br J Nutr. 2002. 87:Suppl 1. S3–S8.

24. Xu J, Yunshi Z, Li R. Immunonutrition in surgical patients. Curr Drug Targets. 2009. 10:771–777.

25. Klek S. Immunonutrition in cancer patients. Nutrition. 2011. 27:144–145.

26. Ziegler TR, Young LS, Benfell K, Scheltinga M, Hortos K, Bye R, et al. Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. Ann Intern Med. 1992. 116:821–828.

27. van Zaanen HC, van der Lelie H, Timmer JG, Fürst P, Sauerwein HP. Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity. Cancer. 1994. 74:2879–2884.

28. Noé JE. L-glutamine use in the treatment and prevention of mucositis and cachexia: a naturopathic perspective. Integr Cancer Ther. 2009. 8:409–415.

29. Izaola O, de Luis DA, Cuellar L, Terroba MC, Ventosa M, Martin T, et al. Influence of an immuno-enhanced formula in postsurgical ambulatory patients with head and neck cancer. Nutr Hosp. 2010. 25:793–796.

30. Singleton KD, Serkova N, Beckey VE, Wischmeyer PE. Glutamine attenuates lung injury and improves survival after sepsis: role of enhanced heat shock protein expression. Crit Care Med. 2005. 33:1206–1213.

31. O'Riordain MG, De Beaux A, Fearon KC. Effect of glutamine on immune function in the surgical patient. Nutrition. 1996. 12:S82–S84.

32. Lu CY, Shih YL, Sun LC, Chuang JF, Ma CJ, Chen FM, et al. The inflammatory modulation effect of glutamine-enriched total parenteral nutrition in postoperative gastrointestinal cancer patients. Am Surg. 2011. 77:59–64.

33. Lecleire S, Hassan A, Marion-Letellier R, Antonietti M, Savoye G, Bôle-Feysot C, et al. Combined glutamine and arginine decrease proinflammatory cytokine production by biopsies from Crohn's patients in association with changes in nuclear factor-kappaB and p38 mitogen-activated protein kinase pathways. J Nutr. 2008. 138:2481–2486.

34. Ziegler TR, Ogden LG, Singleton KD, Luo M, Fernandez-Estivariz C, Griffith DP, et al. Parenteral glutamine increases serum heat shock protein 70 in critically ill patients. Intensive Care Med. 2005. 31:1079–1086.

35. Singleton KD, Serkova N, Beckey VE, Wischmeyer PE. Glutamine attenuates lung injury and improves survival after sepsis: role of enhanced heat shock protein expression. Crit Care Med. 2005. 33:1206–1213.

36. van de Poll MC, Ligthart-Melis GC, Boelens PG, Deutz NE, van Leeuwen PA, Dejong CH. Intestinal and hepatic metabolism of glutamine and citrulline in humans. J Physiol. 2007. 581:819–827.

37. van de Poll MC, Siroen MP, van Leeuwen PA, Soeters PB, Melis GC, Boelens PG, et al. Interorgan amino acid exchange in humans: consequences for arginine and citrulline metabolism. Am J Clin Nutr. 2007. 85:167–172.

38. Déchelotte P, Hasselmann M, Cynober L, Allaouchiche B, Coëffier M, Hecketsweiler B, et al. L-alanyl-L-glutamine dipeptide-supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: the French controlled, randomized, double-blind, multicenter study. Crit Care Med. 2006. 34:598–604.

39. Cario E, Rosenberg IM, Brandwein SL, Beck PL, Reinecker HC, Podolsky DK. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors. J Immunol. 2000. 164:966–972.

40. Kessel A, Toubi E, Pavlotzky E, Mogilner J, Coran AG, Lurie M, et al. Treatment with glutamine is associated with down-regulation of Toll-like receptor-4 and myeloid differentiation factor 88 expression and decrease in intestinal mucosal injury caused by lipopolysaccharide endotoxaemia in a rat. Clin Exp Immunol. 2008. 151:341–347.

41. Abreu MT, Vora P, Faure E, Thomas LS, Arnold ET, Arditi M. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol. 2001. 167:1609–1616.

42. Boelens PG, Melis GC, van Leeuwen PA, ten Have GA, Deutz NE. Route of administration (enteral or parenteral) affects the contribution of L-glutamine to de novo L-arginine synthesis in mice: a stable-isotope study. Am J Physiol Endocrinol Metab. 2006. 291:E683–E690.

43. Haynes TE, Li P, Li X, Shimotori K, Sato H, Flynn NE, et al. L-Glutamine or L-alanyl-L-glutamine prevents oxidant- or endotoxin-induced death of neonatal enterocytes. Amino Acids. 2009. 37:131–142.

44. Ligthart-Melis GC, van de Poll MC, Dejong CH, Boelens PG, Deutz NE, van Leeuwen PA. The route of administration (enteral or parenteral) affects the conversion of isotopically labeled L-[2-15N]glutamine into citrulline and arginine in humans. JPEN J Parenter Enteral Nutr. 2007. 31:343–348.

45. Fuentes-Orozco C, Anaya-Prado R, González-Ojeda A, Arenas-Márquez H, Cabrera-Pivaral C, Cervantes-Guevara G, et al. L-alanyl-L-glutamine-supplemented parenteral nutrition improves infectious morbidity in secondary peritonitis. Clin Nutr. 2004. 23:13–21.

46. Loï C, Zazzo JF, Delpierre E, Niddam C, Neveux N, Curis E, et al. Increasing plasma glutamine in postoperative patients fed an arginine-rich immune-enhancing diet--a pharmacokinetic randomized controlled study. Crit Care Med. 2009. 37:501–509.

47. Sevastiadou S, Malamitsi-Puchner A, Costalos C, Skouroliakou M, Briana DD, Antsaklis A, et al. The impact of oral glutamine supplementation on the intestinal permeability and incidence of necrotizing enterocolitis/septicemia in premature neonates. J Matern Fetal Neonatal Med. 2011. [Epub ahead of print].

48. Houdijk AP, Rijnsburger ER, Jansen J, Wesdorp RI, Weiss JK, McCamish MA, et al. Randomised trial of glutamine-enriched enteral nutrition on infectious morbidity in patients with multiple trauma. Lancet. 1998. 352:772–776.

49. Wernerman J, Kirketeig T, Andersson B, Berthelson H, Ersson A, Friberg H, et al. Scandinavian glutamine trial: a pragmatic multi-centre randomised clinical trial of intensive care unit patients. Acta Anaesthesiol Scand. 2011. 55:812–818.

50. Cetinbas F, Yelken B, Gulbas Z. Role of glutamine administration on cellular immunity after total parenteral nutrition enriched with glutamine in patients with systemic inflammatory response syndrome. J Crit Care. 2010. 25:661.e1–661.e6.

51. Oudemans-van Straaten HM, Bosman RJ, Treskes M, van der Spoel HJ, Zandstra DF. Plasma glutamine depletion and patient outcome in acute ICU admissions. Intensive Care Med. 2001. 27:84–90.

52. Novak F, Heyland DK, Avenell A, Drover JW, Su X. Glutamine supplementation in serious illness: a systematic review of the evidence. Crit Care Med. 2002. 30:2022–2029.

53. Schloerb PR, Amare M. Total parenteral nutrition with glutamine in bone marrow transplantation and other clinical applications (a randomized, double-blind study). JPEN J Parenter Enteral Nutr. 1993. 17:407–413.

54. Scolapio JS. Treatment of short-bowel syndrome. Curr Opin Clin Nutr Metab Care. 2001. 4:557–560.

55. Coëffier M, Marion-Letellier R, Déchelotte P. Potential for amino acids supplementation during inflammatory bowel diseases. Inflamm Bowel Dis. 2010. 16:518–524.

56. Lacey JM, Crouch JB, Benfell K, Ringer SA, Wilmore CK, Maguire D, et al. The effects of glutamine-supplemented parenteral nutrition in premature infants. JPEN J Parenter Enteral Nutr. 1996. 20:74–80.

57. Wang Y, Tao YX, Cai W, Tang QY, Feng Y, Wu J. Protective effect of parenteral glutamine supplementation on hepatic function in very low birth weight infants. Clin Nutr. 2010. 29:307–311.

58. Cohen-Wolkowiez M, Benjamin DK Jr, Capparelli E. Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis. Curr Opin Pediatr. 2009. 21:177–181.